Technology
Using proprietary drug delivery technologies, SkyePharma develops new formulations of both existing products as well as new chemical entities to provide a clinical benefit to patients.
By accessing our technology, know how and experience, our partners can acquire the following benefits for their products:
Product enhancement
- Maximize product potential
- Expand return on investment
Reduce regulatory hurdles via
- Orphan drug/paediatric exclusivity
- Already approved technology
Added product value through
- Improved compliance, tolerance, dosing, efficacy, safety
Increased product differentiation
Expanded indications
- Repositioning expands franchise.
Access versatile platform to apply across product range
Increased profitability
- Lower cost of goods
- Improve manufacturability
Copyright 2012, SkyePharma. All Rights Reserved.
SkyePharma PLC is a public limited company registered in England and Wales, registration number 0107582.
Registered office: 46-48 Grosvenor Gardens, London SW1W 0EB, United Kingdom